UBS Group
SNTI icon

UBS Group’s Senti Biosciences Holdings SNTI Stock Holding History

UBS Group’s Portfolio SNTI Stock Details SNTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.9K Buy
14,432
+5,795
+67% +$5.67K ﹤0.01% 8300
2026
Q1 		$7.01K Buy
8,637
+4,108
+91% +$3.97K ﹤0.01% 8632
2025
Q4 		$4.71K Buy
+4,529
New +$8.01K ﹤0.01% 8794
2025
Q3 		– Sell
-4,412
Closed -$9.31K – 10877
2025
Q2 		$9.31K Sell
4,412
-39,072
-90% -$124K ﹤0.01% 8894
2025
Q1 		$146K Buy
43,484
+24,515
+129% +$95.4K ﹤0.01% 6762
2024
Q4 		$66.6K Buy
18,969
+8,472
+81% +$27K ﹤0.01% 7119
2024
Q3 		$23.7K Buy
+10,497
New +$27.7K ﹤0.01% 7270
2024
Q2 		– Sell
-73
Closed -$276 – 10038
2024
Q1 		$276 Buy
+73
New +$326 ﹤0.01% 8662
2023
Q4 		– Sell
-20
Closed -$83 – 9840
2023
Q3 		$83 Buy
+20
New +$138 ﹤0.01% 8929
2023
Q2 		– Sell
-540
Closed -$6.37K – 9581
2023
Q1 		$6.37K Sell
540
-42
-7% -$654 ﹤0.01% 7926
2022
Q4 		$8.2K Sell
582
-383
-40% -$9.34K ﹤0.01% 8804
2022
Q3 		$21K Buy
965
+964
+96,400% +$19K ﹤0.01% 7339
2022
Q2 		$0 Sell
1
-214
-100% -$17.2K ﹤0.01% 10893
2022
Q1 		$21K Buy
+215
New +$21.2K ﹤0.01% 7404

Other funds holding SNTI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
MVM
Menlo Ventures Management Menlo Park, California $357M AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

UBS Group's SNTI Position: Q2 2026 in Review

UBS Group increased its Senti Biosciences Holdings (SNTI) stake by 67% in Q2 2026, buying an estimated $5.67K and bringing the position to 14,432 shares worth $15.9K. The position accounts for ﹤0.01% of the portfolio, ranked #8300.

UBS Group first reported a position in SNTI in Q1 2022 and has held it in 14 quarters since. The position peaked at $146K in Q1 2025. 19 funds tracked by Wall St. Rank hold SNTI as of Q2 2026.

  • UBS Group held 14,432 shares of Senti Biosciences Holdings worth $15.9K as of Q2 2026.
  • UBS Group bought 5,795 Senti Biosciences Holdings shares in Q2 2026, an estimated $5.67K.
  • Senti Biosciences Holdings made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8300 holding.
  • UBS Group first reported a position in Senti Biosciences Holdings in Q1 2022 and has held it in 14 quarters since.
  • UBS Group's Senti Biosciences Holdings position peaked at $146K in Q1 2025.
  • 19 funds tracked by Wall St. Rank held Senti Biosciences Holdings as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.